Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 2 of 9312345...102030...Last »

ProQR childhood blindness drug succeeds in early study

An interim analysis of an early-stage trial showed that ProQR Therapeutics NV’s experimental treatment for a rare form of childhood blindness improved vision.

Read More »

Lupus Drug Fails To Meet Main Study Goal

AstraZeneca’s anifrolumab failed to meet the experimental drug’s main target in a late-stage clinical study treating patients with moderate to severe lupus.

Read More »

Pfizer Terminates Two DMD Studies Following Data Review

Pfizer terminated two clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrophy.

Read More »

Companies Continue to Take Aim at Glioblastoma, a Cancer Highlighted by the Death of Sen. John McCain

Citing the National Institutes of Health (NIH), CNN reported there are 274 glioblastoma multiforme studies underway or recruiting across the United States.

Read More »

Esperion’s Bemopedoic Acid Treatments Hit the Mark in Two Studies

Ann Arbor, Mich.-based Esperion Therapeutics reported final results from a long-term safety study of bempedoic acid 180 mg versus placebo in high-risk patients with atherosclerotic cardiovascular disease (ASCVD) whose disease is inadequately controlled by statins.

Read More »

Pfizer rare heart disease drug reduces risk of death by 30 percent in study

Pfizer Inc.’s tafamidis reduced the risk of death for patients with a rare and fatal heart disease by around 30 percent, boosting the prospects of what could be a billion-dollar-a-year drug.

Read More »

Bayer, J&J’s bid to widen use of Xarelto hits snag

Bayer and Johnson & Johnson’s campaign to widen the patient group for the companies’ heart drug Xarelto hit a snag when two smaller studies failed to show a statistically reliant benefit.

Read More »

Computer Program Can Predict How Cancer Tumors Will Respond to Drugs Before Dosing Begins

A new computer tool has been developed to predict how some cancers may respond to an investigational treatment before the drug has even been administered to a patient.

Read More »

Pharmaceutical companies: 3 mindset shifts to deal with a drying pipeline

The difficulty behind new ideas, project management, drug prices, and the slowness and uncertainty of new product development are just some external and internal roadblocks that pharmaceutical leaders and employees face.

Read More »

A Glimpse into the Pancreatic Cancer Pipeline

The passing of singing great Aretha Franklin has focused attention on pancreatic cancer. Franklin, 76, succumbed to a neuroendocrine tumor of the pancreas. According to the National Cancer Institute, pancreatic cancer is relatively rare with about 55,440 cases diagnosed annually, representing about 3.2 percent of new cancer cases.

Read More »

Toxic “Zombie Cells” Observed in Alzheimer’s Patients

Researchers at the University of Texas Health Science Center at San Antonio found a type of cellular stress in Alzheimer’s disease for the first time that is involved in cancer and aging.

Read More »

Novartis trial win lifts profile of new breast cancer drug

Novartis’ efforts to tackle an elusive gene mutation behind tough-to-treat breast cancer were rewarded as the Swiss drugmaker said one of its investigational medicines slowed disease progression.

Read More »

AstraZeneca inhaler lags GSK drug in lung disease trial

A new AstraZeneca inhaler for chronic lung disease proved worse than a rival GlaxoSmithKline product in a clinical trial.

Read More »

Pfizer, Astellas revise two cancer drug trial protocols to speed up results

Drugmakers Pfizer Inc. and Astellas Pharma Inc. said they would change protocols for two late-stage trials testing the prostate cancer drug Xtandi to speed up completion.

Read More »

After Trial Failure, Tonix Sees Glimmer of Hope for Future of PTSD Drug

Shares of Tonix Pharmaceuticals shot up 25 percent in premarket trading after the company announced there may be a future for its late-stage posttraumatic stress disorder treatment Tonmya after a Phase III trial was halted early in July 2018 following a data review showed an inadequate response.

Read More »

Evotec and Novo Nordisk Ink Deal to Develop Drugs for Obesity and Diabetes

Months after partnering with Sanofi on infectious diseases, Germany-based Evotec formed another significant partnership with Novo Nordisk.

Read More »

Moderate ‘bad cholesterol’ levels tied to early death for healthy people

Healthy adults who do not keep their LDL-C, or “bad cholesterol,” in check are more likely to die prematurely from cardiovascular disease than peers with lower cholesterol levels, a U.S. study suggests.

Read More »

Novo Nordisk’s Semaglutide Hits Mark in T2D Trial

Novo Nordisk revealed that oral semaglutide achieved positive results in the PIONEER 5 study for the reduction of blood sugar levels and weight in adults with type 2 diabetes.

Read More »

Staying fit might cut glaucoma risk

Meeting physical activity guidelines and being physically fit may reduce the risk of developing glaucoma by 40 percent to 50 percent, recent research suggests.

Read More »

Links seen between asthma and ADHD

There may be a strong connection between asthma and attention deficit hyperactivity disorder (ADHD) that makes people with one condition more likely to develop the other one, a recent study suggests.

Read More »

Page 2 of 9312345...102030...Last »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!


Ad Right Bottom